Abstract:Human triple negative breast cancer cells, MDA-MB-231, show typical epithelial to mesenchymal transition associated with cancer progression. Mitochondria play a major role in cancer progression, including metastasis. Changes in mitochondrial architecture affect cellular migration, autophagy and apoptosis. Silibinin is reported to have anti-breast cancer effect. We here report that silibinin at lower concentrations (30–90 μM) inhibits epithelial to mesenchymal transition (EMT) of MDA-MB-231, by increasing the expression of epithelial marker, E-cadherin, and decreasing the expression of mesenchymal markers, N-cadherin and vimentin. Besides, silibinin inhibition of cell migration is associated with reduction in the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9) and paxillin. In addition, silibinin treatment increases mitochondrial fusion through down-regulating the expression of mitochondrial fission-associated protein dynamin-related protein 1 (DRP1) and up-regulating the expression of mitochondrial fusion-associated proteins, optic atrophy 1, mitofusin 1 and mitofusin 2. Silibinin perturbed mitochondrial biogenesis via down-regulating the levels of mitochondrial biogenesis regulators including mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated receptor gamma coactivator (PGC1) and nuclear respiratory factor (NRF2). Moreover, DRP1 knockdown or silibinin inhibited cell migration, and MFN1&2 knockdown restored it. Mitochondrial fusion contributes to silibinin's negative effect on cell migration. Silibinin decreased reactive oxygen species (ROS) generation, leading to inhibition of the NLRP3 inflammasome activation. In addition, knockdown of mitofusin 1&2 (MFN 1&2) relieved silibinin-induced inhibition of NLRP3 inflammasome activation. Repression of ROS contributes to the inhibition of the expression of NLRP3, caspase-1 and IL-β proteins as well as of cell migration. Taken together, our study provides evidence that silibinin impairs mitochondrial dynamics and biogenesis, resulting in reduced migration and invasion of the MDA-MB-231 breast cancer cells.

Silibinin Induces Apoptosis Through Inhibition of the Mtor-Gli1-bcl2 Pathway in Renal Cell Carcinoma.

Silibinin induces apoptosis by caspase activation , down-regulating Bcl-2 and activating YAP / p 53 in renal cell carcinoma

Silibinin Inhibits Epithelial‑mesenchymal Transition of Renal Cell Carcinoma Through Autophagy‑dependent Wnt/β‑catenin Signaling.

Silibinin Inhibits Cell Growth and Induces Apoptosis by Caspase Activation, Down-Regulating Survivin and Blocking EGFR–ERK Activation in Renal Cell Carcinoma

Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma

Inhibitory Effect of Silibinin on EGFR Signal-Induced Renal Cell Carcinoma Progression Via Suppression of the EGFR/MMP-9 Signaling Pathway.

Silibinin inhibits the stem cell property of renal cell carcinoma through Wnt/β-catenin signaling

Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells.

Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy Through Simultaneous Inhibition of Mtor and YAP

Evaluation of Anti-Cancer Potency of Silibinin on Murine Renal Carcinoma RenCa Cells in an Animal Model with an Intact Immune System

Silibinin Inhibits Β-Catenin/zeb1 Signaling and Suppresses Bladder Cancer Metastasis Via Dual-Blocking Epithelial–mesenchymal Transition and Stemness

Silibinin Induces G1 Arrest, Apoptosis and JNK/SAPK Upregulation in SW1990 Human Pancreatic Cancer Cells.

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells

Role of Heat Shock Protein 70 in Silibinin-Induced Apoptosis in Bladder Cancer.

Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion

Silibinin Inhibited Autophagy and Mitochondrial Apoptosis in Pancreatic Carcinoma by Activating JNK/SAPK Signaling.

Anti-Tumor Activity and Mechanism of Silibinin Based on Network Pharmacology and Experimental Verification

Targeting silibinin in the antiproliferative pathway.

Silibinin Inhibits Wnt/β-catenin Signaling by Suppressing Wnt Co-Receptor LRP6 Expression in Human Prostate and Breast Cancer Cells

Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.

Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells